BioNexus Launches BGLC 1Lab Pilot for GeneMatrix Workflows at MRNA Scientific
Globe Newswire•03/11/2026•09:00 ET
0
Key Highlights
- ➤BioNexus (BGLC) introduced BGLC 1Lab laboratory workflow product
- ➤1Lab launched as controlled GeneMatrix pilot at MRNA Scientific in Penang
- ➤GeneMatrix Enterprise workflow testing completed; broader release remains subject to validation
- ➤Ruanyun (RYET) CogniAI integration awaits license closing and required approvals
Expert Statements
Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp.
“We are in a transition phase in our healthcare business, toward services that can integrate with increasingly autonomous AI. We believe an important part of AI’s next phase of growth will come from connecting advances in large language models with the data and workflows needed to deliver useful services. We are developing 1Lab around laboratory operations, customer reporting and private AI, with qualified professionals retaining responsibility for laboratory and clinical decisions.”
KUALA LUMPUR, Malaysia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company") today introduced BGLC 1Lab, its laboratory workflow product, and announced its initial launch as a controlled GeneMatrix-focused pilot at its MRNA Scientific Sdn. Bhd. subsidiary. A dedicated product mini-site is available at www.bionexusgenelab.com/1lab.
1Lab is designed to connect clinic orders, specimen reception, bench activity, scientific review and report delivery in one traceable record. The workflow design links each step to accountable staff and makes a test’s progress and exceptions visible.
Get started
Create a free account to read the full story.